New Delhi: The World Health Organization (WHO) on Wednesday (June 3, 2020) introduced to resumed the trial of hydroxychloroquine drug which was temporarily paused on May 25 as a result of of issues raised concerning the security of the drug.
Director-General of the World Health Organization, Dr Tedros Adhanom Ghebreyesus stated, “On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol. The Executive Group received this recommendation and endorsed the continuation of all arms of the Solidarity Trial, including hydroxychloroquine.”
On the sooner choice, the WHO DG stated it was taken as a precaution whereas the protection information had been reviewed.
He additional said the Executive Group will talk with the principal investigators within the trial about resuming the hydroxychloroquine arm.
“The Data Safety and Monitoring Committee will continue to closely monitor the safety of all therapeutics being tested in the Solidarity Trial,” added Dr Tedros.
He additionally stated that greater than 1,00,000 instances of COVID-19 have been reported to WHO for every of the previous 5 days.
“The Americas continue to account for most cases. For several weeks, the number of cases reported each day in the Americas has been more than the rest of the world put together.”
“We are especially worried about Central and South America, where many countries are witnessing accelerating epidemics. We also see increasing numbers of cases in the Eastern Mediterranean, South-East Asia, and Africa, although the numbers are much smaller,” stated Dr Tedros.
He knowledgeable the quantity of instances in Europe continues to say no.
“Yesterday saw the fewest cases reported in Europe since March 22.”
“WHO continues to work through our regional and country offices to monitor the pandemic, to support countries to respond, and to adapt our guidance for every situation,” stated Dr Tedros.